Management of Thrombotic Risk in Bioprosthetic Valves

Initial Antithrombotic Management After Bioprosthetic Valve Implantation

The American College of Cardiology recommends aspirin 75-100 mg daily as standard antithrombotic therapy after the initial postoperative period, with vitamin K antagonist (VKA) anticoagulation recommended for the first 3-6 months after valve implantation to reduce thrombotic risk 1, 2, 3
For patients with surgical bioprosthetic aortic valve replacement, VKA anticoagulation with an INR goal of 2.5 (range 2.0-3.0) is reasonable for at least 3 months and up to 6 months after surgery, as recommended by the American College of Cardiology 1, 2
A large Danish registry demonstrated that VKA therapy extending up to 6 months after bioprosthetic AVR is associated with a lower risk of stroke and death without significantly increased bleeding risk, as reported in the Journal of the American College of Cardiology 4
After the initial 3-6 month period, lifelong aspirin 75-100 mg daily is recommended for patients without other indications for anticoagulation, according to the American Heart Association 2, 3

In patients with bioprosthetic valves who experience a stroke or systemic embolic event while on antiplatelet therapy, VKA anticoagulation may be considered after assessment of bleeding risk, as suggested by the American College of Cardiology 6, 7
When evaluating thromboembolic events, it's essential to rule out infective endocarditis, new-onset atrial fibrillation, and consider whether an underlying hypercoagulable state might be contributing, as recommended by the American Heart Association 7

Transthoracic echocardiography (TTE) is indicated as the first step in evaluation of suspected prosthetic valve thrombosis to assess hemodynamic severity, according to the American College of Cardiology 8, 9
Transesophageal echocardiography (TEE) is more sensitive for detection of valve thrombosis, especially of mitral prosthetic valves, as reported in Circulation 9

For patients with both mechanical and bioprosthetic valves, antithrombotic management should follow the more stringent recommendations for mechanical valves, as recommended by the American College of Cardiology 1

Inadequate anticoagulation in the early postoperative period (first 3-6 months) may increase risk of valve thrombosis and thromboembolic events, as reported in Circulation 2, 3
Subclinical bioprosthetic valve leaflet thrombosis can occur after surgical valve replacement and may not be detected by standard echocardiography, as reported in the Journal of the American College of Cardiology 4
Regular monitoring of valve function with echocardiography is essential to detect early signs of valve thrombosis or dysfunction, according to the American College of Cardiology 9